A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Closing the Information Gap: ETH Zürich Team Integrates Function and Binding in One Drug Screening Assay
In a significant advancement poised to reshape the landscape of pharmaceutical development, a collaborative team from ETH Zürich and the…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry grapples with an intractable problem: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
From List Price to Net Price: How Finance Leaders Decode Real Drug Costs
In the intricate landscape of the healthcare industry, public discourse surrounding drug pricing frequently begins and ends with the list…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…
Read More
MEDVi’s Meteoric AI-Fueled Ascent Faces Scrutiny Amidst FDA Warnings, Allegations of Deceptive Marketing, and Multiple Lawsuits
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical industry in Fiscal Year 2025 was defined by a dynamic interplay of enduring blockbuster powerhouses and the dramatic…
Read MoreYOU MAY HAVE MISSED
